Skip to main content

Movement Disorders

0
Pipeline Programs
6
Companies
7
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
2 programs
Deep Brain StimulationN/A1 trial
Infinity DBS System with MR Conditional labellingN/A1 trial
Active Trials
NCT04071847Recruiting1,000Est. Sep 2030
NCT03884231Completed74Est. Aug 2021
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
2 programs
Doubly-Labeled WaterN/A1 trial
Leveraging Machine Learning to Effortlessly Track Patient Movement in the Clinic.N/A1 trial
Active Trials
NCT05736302Recruiting125Est. Dec 2026
NCT04074772Completed25Est. Oct 2021
Insightec
InsightecFL - Miami
2 programs
Exablate Pallidotomy, UnilateralN/A1 trial
Transcranial ExAblate SystemN/A1 trial
Active Trials
NCT05539196Recruiting60Est. Jul 2029
NCT02252380Active Not Recruiting10Est. Dec 2026
Medtronic
MedtronicNJ - Phillipsburg
1 program
Investigation of Non-Invasive Outcomes Predictors in Patients Undergoing DBS for Movement DisordersN/A1 trial
Active Trials
NCT02488837Completed21Est. Dec 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Colorado TherapeuticsDoubly-Labeled Water
InsightecExablate Pallidotomy, Unilateral
Colorado TherapeuticsLeveraging Machine Learning to Effortlessly Track Patient Movement in the Clinic.
AbbottDeep Brain Stimulation
AbbottInfinity DBS System with MR Conditional labelling
InsightecTranscranial ExAblate System
MedtronicInvestigation of Non-Invasive Outcomes Predictors in Patients Undergoing DBS for Movement Disorders

Clinical Trials (7)

Total enrollment: 1,315 patients across 7 trials

NCT05736302Colorado TherapeuticsDoubly-Labeled Water

Validating a New Machine-Learned Accelerometer Algorithm Using Doubly Labeled Water

Start: Mar 2023Est. completion: Dec 2026125 patients
N/ARecruiting
NCT05539196InsightecExablate Pallidotomy, Unilateral

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

Start: Jan 2023Est. completion: Jul 202960 patients
N/ARecruiting
NCT04074772Colorado TherapeuticsLeveraging Machine Learning to Effortlessly Track Patient Movement in the Clinic.

Leveraging Machine Learning to Effortlessly Track Patient Movement in the Clinic.

Start: Dec 2020Est. completion: Oct 202125 patients
N/ACompleted
NCT04071847AbbottDeep Brain Stimulation

Abbott DBS Post-Market Study of Outcomes for Indications Over Time

Start: Nov 2019Est. completion: Sep 20301,000 patients
N/ARecruiting
NCT03884231AbbottInfinity DBS System with MR Conditional labelling

A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling

Start: Apr 2019Est. completion: Aug 202174 patients
N/ACompleted
NCT02252380InsightecTranscranial ExAblate System

ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

Start: May 2015Est. completion: Dec 202610 patients
N/AActive Not Recruiting
NCT02488837MedtronicInvestigation of Non-Invasive Outcomes Predictors in Patients Undergoing DBS for Movement Disorders

Investigation of Non-Invasive Outcomes Predictors in Patients Undergoing DBS for Movement Disorders

Start: Jun 2014Est. completion: Dec 201621 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 1,315 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.